Please use this identifier to cite or link to this item: https://doi.org/10.1530/EDM-16-0043
Title: Sirolimus therapy in a child with partially diazoxide-responsive hyperinsulinaemic hypoglycaemia
Authors: Loke, Kah-Yin 
Anjian, Andrew Sng 
Yijuan, Yvonne Lim 
Li, Cindy Ho Wei
Guemes, Maria
Hussain, Khalid
Keywords: 1115 Pharmacology and Pharmaceutical Sciences
Clinical Medicine and Science
Brain Disorders
Pediatric
6.1 Pharmaceuticals
Issue Date: Oct-2016
Publisher: Bioscientifica
Citation: Loke, Kah-Yin, Anjian, Andrew Sng, Yijuan, Yvonne Lim, Li, Cindy Ho Wei, Guemes, Maria, Hussain, Khalid (2016-10). Sirolimus therapy in a child with partially diazoxide-responsive hyperinsulinaemic hypoglycaemia. ENDOCRINOLOGY DIABETES AND METABOLISM CASE REPORTS 2016. ScholarBank@NUS Repository. https://doi.org/10.1530/EDM-16-0043
Abstract: Hyperinsulinaemic hypoglycaemia (HH), which causes persistent neonatal hypoglycaemia, can result in neurological damage and it's management is challenging. Diazoxide is the first-line treatment, albeit not all patients will fully respond to it, as episodes of hypoglycaemia may persist and it entails unpleasant adverse effects. Sirolimus, an mTOR inhibitor, has reportedly been successful in treating children with severe diffuse HH, thus obviating the need for pancreatectomy. We report a girl with HH, with a novel heterozygous ABCC8 gene missense mutation (c.4154A>T/ p.Lys1385Thr), who was initially responsive to diazoxide therapy. After 11 months of diazoxide treatment, she developed intermittent, unpredictable breakthrough episodes of hypoglycaemia, in addition to generalized hypertrichosis and weight gain from enforced feeding to avoid hypoglycaemia. Sirolimus, which was commenced at 15 months of age, gradually replaced diazoxide, with significant reduction and abolition of hypoglycaemia. The hypertrichosis resolved and there was less weight gain given the reduced need for enforced feeding. Sirolimus, which was administered over the next 15 months, was well tolerated with no significant side effects and was gradually weaned off. After stopping sirolimus, apart from hypoglycaemia developing during an episode of severe viral gastroenteritis, the capillary glucose concentrations were maintained >3.5 mmol/L, even after a 10 h fast. Sirolimus may have a role in the treatment of partially diazoxide-responsive forms of HH who experience breakthrough hypoglycaemia, but the long-term safety and efficacy of sirolimus are not established. LEARNING POINTS: Conventional treatment of diffuse HH with diazoxide is not always effective in controlling hypoglycaemia and can be associated with unpleasant side effects.Sirolimus was successfully used to abolish recurrent hypoglycaemia in partially diazoxide-responsive HH, with resolution of unacceptable diazoxide-associated side effects.Sirolimus was well tolerated with no clinically significant side effects.Shortly after stopping sirolimus, the capillary glucose levels remained normoglycemic.
Source Title: ENDOCRINOLOGY DIABETES AND METABOLISM CASE REPORTS
URI: https://scholarbank.nus.edu.sg/handle/10635/206139
ISSN: 20520573
DOI: 10.1530/EDM-16-0043
Appears in Collections:Staff Publications
Elements

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
Sirolimus therapy in a child with partially diazoxide-responsive hyperinsulinaemic hypoglycaemia.pdfPublished version543.84 kBAdobe PDF

OPEN

PublishedView/Download

Page view(s)

61
checked on Jun 23, 2022

Download(s)

1
checked on Jun 23, 2022

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.